Evidence map›Paper›PMID 27330683›Full record

ArticleWorld journal of hepatology2016

Circulating insulin-like growth factor-binding protein 3 as prognostic biomarker in liver cirrhosis.

Carina Gabriela Correa, Bruno da Silveira Colombo, Marcelo Fernando Ronsoni, Pedro Eduardo Soares E Silva, Leonardo Fayad, Telma Erotides Silva, Letícia Muraro Wildner, Maria Luiza Bazzo, Esther Buzaglo Dantas-Correa, Janaína Luz Narciso-Schiavon and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Insulin-Like Growth Factor (IGF) System in Liver Diseases.International journal of molecular sciences · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Carina Gabriela CorreaCarina Gabriela Correa, Bruno da Silveira Colombo, Marcelo Fernando Ronsoni, Pedro Eduardo Soares e Silva, Leonardo Fayad, Telma Erotides Silva, Esther Buzaglo Dantas-Correa, Janaína Luz Narciso-Schiavon, Leonardo de Lucca Schiavon, Division of Gastroenterology, Federal University of Santa Catarina, Florianópolis, Santa Catarina 88.040-001, Brazil.
Bruno da Silveira ColomboCarina Gabriela Correa, Bruno da Silveira Colombo, Marcelo Fernando Ronsoni, Pedro Eduardo Soares e Silva, Leonardo Fayad, Telma Erotides Silva, Esther Buzaglo Dantas-Correa, Janaína Luz Narciso-Schiavon, Leonardo de Lucca Schiavon, Division of Gastroenterology, Federal University of Santa Catarina, Florianópolis, Santa Catarina 88.040-001, Brazil.
Marcelo Fernando RonsoniCarina Gabriela Correa, Bruno da Silveira Colombo, Marcelo Fernando Ronsoni, Pedro Eduardo Soares e Silva, Leonardo Fayad, Telma Erotides Silva, Esther Buzaglo Dantas-Correa, Janaína Luz Narciso-Schiavon, Leonardo de Lucca Schiavon, Division of Gastroenterology, Federal University of Santa Catarina, Florianópolis, Santa Catarina 88.040-001, Brazil.
Pedro Eduardo Soares E SilvaCarina Gabriela Correa, Bruno da Silveira Colombo, Marcelo Fernando Ronsoni, Pedro Eduardo Soares e Silva, Leonardo Fayad, Telma Erotides Silva, Esther Buzaglo Dantas-Correa, Janaína Luz Narciso-Schiavon, Leonardo de Lucca Schiavon, Division of Gastroenterology, Federal University of Santa Catarina, Florianópolis, Santa Catarina 88.040-001, Brazil.
Leonardo FayadCarina Gabriela Correa, Bruno da Silveira Colombo, Marcelo Fernando Ronsoni, Pedro Eduardo Soares e Silva, Leonardo Fayad, Telma Erotides Silva, Esther Buzaglo Dantas-Correa, Janaína Luz Narciso-Schiavon, Leonardo de Lucca Schiavon, Division of Gastroenterology, Federal University of Santa Catarina, Florianópolis, Santa Catarina 88.040-001, Brazil.
Telma Erotides SilvaCarina Gabriela Correa, Bruno da Silveira Colombo, Marcelo Fernando Ronsoni, Pedro Eduardo Soares e Silva, Leonardo Fayad, Telma Erotides Silva, Esther Buzaglo Dantas-Correa, Janaína Luz Narciso-Schiavon, Leonardo de Lucca Schiavon, Division of Gastroenterology, Federal University of Santa Catarina, Florianópolis, Santa Catarina 88.040-001, Brazil.
Letícia Muraro WildnerCarina Gabriela Correa, Bruno da Silveira Colombo, Marcelo Fernando Ronsoni, Pedro Eduardo Soares e Silva, Leonardo Fayad, Telma Erotides Silva, Esther Buzaglo Dantas-Correa, Janaína Luz Narciso-Schiavon, Leonardo de Lucca Schiavon, Division of Gastroenterology, Federal University of Santa Catarina, Florianópolis, Santa Catarina 88.040-001, Brazil.
Maria Luiza BazzoCarina Gabriela Correa, Bruno da Silveira Colombo, Marcelo Fernando Ronsoni, Pedro Eduardo Soares e Silva, Leonardo Fayad, Telma Erotides Silva, Esther Buzaglo Dantas-Correa, Janaína Luz Narciso-Schiavon, Leonardo de Lucca Schiavon, Division of Gastroenterology, Federal University of Santa Catarina, Florianópolis, Santa Catarina 88.040-001, Brazil.
Esther Buzaglo Dantas-CorreaCarina Gabriela Correa, Bruno da Silveira Colombo, Marcelo Fernando Ronsoni, Pedro Eduardo Soares e Silva, Leonardo Fayad, Telma Erotides Silva, Esther Buzaglo Dantas-Correa, Janaína Luz Narciso-Schiavon, Leonardo de Lucca Schiavon, Division of Gastroenterology, Federal University of Santa Catarina, Florianópolis, Santa Catarina 88.040-001, Brazil.
Janaína Luz Narciso-SchiavonCarina Gabriela Correa, Bruno da Silveira Colombo, Marcelo Fernando Ronsoni, Pedro Eduardo Soares e Silva, Leonardo Fayad, Telma Erotides Silva, Esther Buzaglo Dantas-Correa, Janaína Luz Narciso-Schiavon, Leonardo de Lucca Schiavon, Division of Gastroenterology, Federal University of Santa Catarina, Florianópolis, Santa Catarina 88.040-001, Brazil.
Leonardo de Lucca SchiavonCarina Gabriela Correa, Bruno da Silveira Colombo, Marcelo Fernando Ronsoni, Pedro Eduardo Soares e Silva, Leonardo Fayad, Telma Erotides Silva, Esther Buzaglo Dantas-Correa, Janaína Luz Narciso-Schiavon, Leonardo de Lucca Schiavon, Division of Gastroenterology, Federal University of Santa Catarina, Florianópolis, Santa Catarina 88.040-001, Brazil.
Creative Research Enterprises (United States) · USUniversidade Federal de Santa Catarina · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate the prognostic significance of insulin-like growth factor-binding protein 3 (IGFBP-3) in patients with cirrhosis.

methodsProspective study that included two cohorts: outpatients with stable cirrhosis (n = 138) and patients hospitalized for acute decompensation (n = 189). Development of complications, mortality or liver transplantation was assessed by periodical phone calls and during outpatient visits. The cohort of stable cirrhosis also underwent clinical and laboratory evaluation yearly (2013 and 2014) in predefined study visits. In patients with stable cirrhosis, IGFBP-3 levels were measured at baseline (2012) and at second re-evaluation (2014). In hospitalized subjects, IGFBP-3 levels were measured in serum samples collected in the first and in the third day after admission and stored at -80 °C. IGFBP-3 levels were measured by immunochemiluminescence.

resultsIGFBP-3 levels were lower in hospitalized patients as compared to outpatients (0.94 mcg/mL vs 1.69 mcg/mL, P < 0.001) and increased after liver transplantation (3.81 mcg/mL vs 1.33 mcg/mL, P = 0.008). During the follow-up of the stable cohort, 17 patients died and 11 received liver transplantation. Bivariate analysis showed that death or transplant was associated with lower IGFBP-3 levels (1.44 mcg/mL vs 1.74 mcg/mL, P = 0.027). The Kaplan-Meier transplant-free survival probability was 88.6% in patients with IGFBP-3 ≥ 1.67 mcg/mL and 72.1% for those with IGFBP3 < 1.67 mcg/mL (P = 0.015). In the hospitalized cohort, 30-d mortality was 24.3% and was independently associated with creatinine, INR, SpO2/FiO2 ratio and IGFBP-3 levels in the logistic regression. The 90-d transplant-free survival probability was 80.4% in patients with IGFBP-3 ≥ 0.86 mcg/mL and 56.1% for those with IGFBP3 < 0.86 mcg/mL (P < 0.001).

conclusionLower IGFBP-3 levels were associated with worse outcomes in patients with cirrhosis, and might represent a promising prognostic tool that can be incorporated in clinical practice.

Indexed as

Acute decompensationAcute-on-chronic liver failureInsulin-like growth factor binding protein 3Liver cirrhosisPrognosis

Identifiers

PMID27330683
PMCPMC4911508
OpenAlexW2425067251

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.